Virios therapeutics achieves over 50% enrollment milestone in its phase 2b clinical trial for fibromyalgia

Atlanta--(business wire)---- $viri #biotech--virios therapeutics, inc. (nasdaq: viri), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that more than 50% of the patients planned for the phase 2b fortress (fibromyalgia outcome research trial evaluating synergistic suppression of hsv-1) study have been randomized. the fortress study is a randomized, double-blind evaluation of imc-1 in patients wi
VIRI Ratings Summary
VIRI Quant Ranking